Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 329687

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 18

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Antibody
  • Vaccine
  • cell therapy
  • DNA
  • HIV / AIDs
  • Disease
  • Therapeutic
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 329687

License Grant
The Swiss Licensor, an international non-profit cancer research organization, grants to Licensee an exclusive license under the Licensed Patent Rights to research, develop, make, have made, import have imported. use. have used, sell, have sold, offer for sale, have offered for sale and otherwise exploit Licensed Products in the Field throughout the world.
License Property
Licensed Product means any products the making, selling, using or importing of which is covered by a Valid Claim of a Licensed Patent Right and is (i) an ALK-1 Receptor Product; (ii) an ALK-1 Antibody Product; (iii) an ALK-2 Receptor Product; (iv) an ALK-3 Receptor Product; (v) an ALK-3 Antibody Product; (vi) an ALK4 Receptor Product; (vii) an ALK-4 Antibody Product (viii) an ALK-5 Receptor Product (ix) an ALK-5 Antibody Product; (x) an ALK-6 Receptor Product; (xi) an ALK-6 Antibody Product.

ALK-1 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-1 receptor, as exemplified by amino acids 1-118 of the human ALK-1 sequence presented in U.S. Patent No. 6,316217, or an active po11ion thereof.

ALK-1 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-1 receptor.

ALK-2 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-2 receptor, as exemplified by amino acids 1-124 of the human ALK-2 sequence presented in C .S. Patent No. 6,316,217 or an active portion thereof.

ALK-3 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-3 receptor, as exemplified by amino acids 1-152 of the human ALK-3 sequence presented in U.S. Patent  6.316,217, or an active portion thereof.

ALK-3 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-3 receptor.

ALK-4 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-4 receptor, as exemplified by amino acids 1-126 of the human ALK-4 sequence presented in U.S. Patent No. 6,316,217, or an active portion thereof.

ALK-4 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-4 receptor.

ALK-5 Receptor Product means any product which is comprised at least in part of an extracellular domain of an ALK-5 receptor, as exemplified by amino acids 1-121 of the human ALK-5 sequence presented in U.S. Patent No. 6,316.217, or an active portion thereof.

ALK-5 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-5 receptor.

ALK-6 Receptor Product means any product which is comprised at!east in part of an extracellular domain of an ALK-6 receptor, as exemplified by amino acids 1-122 of the murine ALK-6 sequence presented in U.S. Patent No. 6,316,217, or an active portion thereof.

ALK-6 Antibody Product means any product which is comprised at least in part of an antibody or a domain of an antibody that binds to an ALK-6 receptor.

Field of Use
The patent rights relate to the first cloning of the type I activin receptors, as well as the treatment of pancreatic tumors with dalantercept.

IPSCIO Record ID: 329688

License Grant
Licensor, a non-profit teaching hospital, grants an exclusive license under Licensors rights in the Patent Rights to make, have made, use, have used, Sell, have Sold, import and have imported Patented Products and Patented Uses.   Licensor grants the right to  grant sublicenses.
License Property
The Patent application is entitled ALK-Fc exhibits activity in Renal cancer murine xenografts as a single agent and in combination with VEGFR inhibition.

mTOR-targeted inhibitor means a direct inhibitor of the protein called the mammalian target of rapamycin. Each of the following compounds is a non-limiting example of an mTOR-targeted inhibitor everolimus and temsirolimus.

ALKl Product means (i) anALKl (activin receptor-like kinase 1) polypeptide comprising a ligand binding portion of the extracellular domain of a vertebrate ALK 1, particularly human ALKl (e.g. a fusion protein including the ALKl ligand binding domain fused to an Fe p01iion of an IgG); (ii) an antibody that binds to the extracellular domain of human ALKl; (iii) an antibody that binds to human BMP9; or (iv) an antibody that binds to human BMPI0. For clarity, proteins that include the amino acid sequence described as SEQ ID NO 3 or SEQ ID NO5 in U.S. Patent No. 8,158,584 are included in the term ALKl Product.

RTKI means a small-molecule receptor tyrosine kinase inhibitor that binds to and inhibits signaling of VEGFRI, VEGFR2, or VEGFR3. An RTKI may, but need not, bind to and inhibit receptor tyrosine kinases in addition to a VEGFR, such as PDGFRa, PDGFRb, RET and c-Met. Likewise, an RTKI may, but need not, inhibit a different class of kinases that are not cell surface receptors, such as the serine kinases B-raf and c-raf kinase. Each of the following compounds is a non-limiting example of an RTKI sorafenib, pazopanib, axitinib, tivozanib, sunitinib, vandetanib, motesanib, vatalanib and samaxanib.

Field of Use
The Patented Use means the use of an ALKI Product and (i) an RTKI or (ii) an mTORtargeted inhibitor, for the treatment of patients with renal cell carcinoma. Patented Use shall include without limitation the sequential, overlapping or simultaneous dosing of patients with an ALKI Product and the RTKI or mTOR-targeted inhibitor. Patented Use shall also include any additional uses of ALKI Products that are the subject of a valid Claim of the Licensed Patents.

IPSCIO Record ID: 372489

License Grant
For the Grant of Licensee Product License by Licensor of the United Kingdom, in the event Licensor notifies Licensee that a Nominated Target has passed the Licensor Gatekeeping Procedure, then, Licensor grants a non-exclusive license, with the right to sublicense, under the Licensor Antibody Phage Display Patents and Licensor Know-How to Exploit Products against such Nominated Target in the Territory.

For Other Products, Licensor grants with effect from  January 3, 2003 to Licensee a non-exclusive license in the Territory, with the right to sublicense, under the Licensor Antibody Phage Display Patents and the Licensor Know-How for any purpose not already covered by the provisions of this Agreement, Other Purposes, including to Exploit any product, other than a Therapeutic Antibody Product, Diagnostic Antibody Product or Research Product, whose development, manufacture, use or sale would, absent the license hereunder, infringe Valid Claims of the Licensor Antibody Phage Display Patents or utilize the Licensor Know-How.

License Property
Licensor is the owner or exclusive licensee of the Licensor Antibody Phage Display Patents.

Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

Catalytic Antibodies means solely those Antibodies which bind to and catalyze the chemical transformation of a substrate and in which an Antibody binding region is involved in said catalysis.

D2E7 means any Antibody directed against the Target TNF alpha.

Licensor Licensable Antibody means any Antibody, including a Bi-Specific Antibody or a PolySpecific Antibody, to a Target where such Antibody has been identified, generated, developed, produced or derived by Licensee or a Licensee Sublicensee.

Product means a Diagnostic Antibody Product or a Therapeutic Antibody Product.

Single Domain Antibodies means an Antibody containing only a single domain, heavy or light.

Target shall mean
— a polynucleotide sequence corresponding to a sequence identified in a publicly available curated database such as GenBank® by means of an accession number or similar sequence information that uniquely identifies that sequence;
— a non-proteinaceous antigen that is uniquely identifiable in a routine manner using publicly available curated databases and/or such other suitable written material as is available.

Antibody Phage Display Patents include Single domain ligands, receptors comprising said ligands, methods for their production and use of said ligands and receptors, and, Cloning immunoglobulin variable domain sequences.

Know-how includes
Licensor mammalian expression lgG vectors
— pEU1.2 (hwnangamma-1 heavy chain)
— pEU3.2 (human kappa light chain)
— pEU4.2 (human lambda light chain)
— pEU8.2 (human gamma-4 heavy chain)

Antibody phage display is a versatile, in vitro selection technology that can be utilized to discover high affinity antibodies specific to a wide variety of antigens (94).

Field of Use
The Field of Use means research and development of human or non-human therapeutics and human or nonhuman in vitro diagnostic or research reagent uses only and not any in vivo diagnostics, purifications or separations, or other industrial purposes.

IPSCIO Record ID: 256276

License Grant
The Licensor of England grants to Licensee of Germany a nonexclusive, worldwide license under the Licensor Licensed Patents and the Licensor Background Know-How to Exploit Licensed Products in the Field.
License Property
Licensor is a UK-based biotechnology company using its proprietary technologies and capabilities in human monoclonal antibodies for drug discovery and drug development.

Licensed Product means any product, substance or formulation arising from the Target Program, and the Development, manufacture, importation, use or sale of which would but for the provisions of this Agreement infringe one or more Valid Claims under the Licensor Licensed Patents, or which utilizes the Licensor Background Know-How.

The know-how includes Training Manual Antibody Phage Display 2002, and, mammalian expression IgG vectors.

Field of Use
The Field means the prognosis, diagnosis, prophylaxis or treatment of human diseases or conditions by modulation of the Target. Target means the whole or part and natural variants of the granulocyte-macrophage colony stimulating factor (GM-CSF) identified by the SWISS-PROT entry name CSF2_HUMAN and accession number P04141 with the amino acid sequence which is specifically recognized by an Antibody binding to the foregoing.

Licensee obtains the right within the framework of their collaboration to use Licensor’s intellectual property in phage display to create and commercialise novel antibody products against a defined number of targets.

IPSCIO Record ID: 289229

License Grant
For Licensed Biologic Products, Licensor grants an exclusive, sub-licensable, worldwide license to Licensee to research, develop, use, make, have made, sell, offer for sale, import or export any Licensed Biologic Products in the Therapeutic Field.

For Licensed Drug Products, Licensor grants an exclusive, sub-licensable, worldwide license to research, develop, use, make, have made, sell, offer for sale, import or export any Licensed Drug Products in the Therapeutic Field.  Notwithstanding the foregoing, Licensee may sublicense a Licensed Drug Product, provided that Licensee has at least one pending patent claim covering such product.

For Developed Drug Products, Licensor grants a non-exclusive, sub-licensable, worldwide license to research, develop, use, make, have made, sell, offer for sale, import or export any Developed Drug Products in the Therapeutic Field. Notwithstanding the foregoing, Licensee may sublicense a Developed Drug Product, provided that Licensee has at least one pending patent claim covering such product.

For Licensed Diagnostic Products, Licensor grants a non-exclusive, sub-licensable, worldwide license to research, develop, use, make, have made, sell, offer for sale, import or export any Licensed Diagnostic Product in the Diagnostic Field. Licensees right to sublicense a Licensed Diagnostic Product will be limited to applications reasonably determined to be necessary for successful commercialization of the Licensed Biologic Product or Licensed Drug Product and subject to Licensors approval, which will not be unreasonably withheld.

License Property
Licensor has intellectual property related to the receptor to the Tumor necrosis factor-like weak inducer of apoptosis, or Tweak-R.

Tweak-R shall mean the receptor to the tumor necrosis factor like weak inducer of apoptosis, which is the molecule designated CG 17M42 by HGS.

Field of Use
'Indication' is a therapeutic indication for a particular disease, and, for example, cancer indications within different organs (e.g., lung cancer and colon cancer) shall not represent different indications.

IPSCIO Record ID: 369382

License Grant
For the Exclusive Licenses, Licensor grants
–  an exclusive license, including the right to sublicense, under the Licensor Patent Rights, to research, develop, make, have made, use, sell, offer for sale, supply, cause to be supplied and import Compounds and Licensed Products in the Territory;
–  an exclusive license, including the right to sublicense, to use Licensor Technology and Confidential information in connection with the research. development, making, having made, use, sale, oiler for sale, supply, causing to be supplied and importation of Compounds and Licensed Products in the Territory;
–  an exclusive license, including the right to sublicense, under the Licensor Patent Rights to research, develop, make, have made, use, sell, offer for sale, supply, cause to be supplied and import Diagnostic Assays in the Territory; and
–  an exclusive license, including the right to sublicense, to use Licensor Technology and Confidential information in connection with the research, development, making, having made, use, sale, offer for sale, supply, causing to be supplied and importation of Diagnostic Assays in the Territory.

For the Non-Exclusive Research License, Licensor grants a non-exclusive, irrevocable, perpetual license in the Territory, with the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology and Confidential Information disclosed to Licensee during the Term, excluding any Patent Rights relating thereto.

License Property
Licensor owns or otherwise controls certain patents, patent applications, technology, know-how and scientific and technical information relating to an EGFRvIII mutant peptide comprising the amino acid sequence LYS-LYS-GLY-ASN-TYR.

CDX-110 means the EGFRvlll mutant peptide consisting of the amino acid sequence LEU-GLU-GLU-LYS-LYS-GLY-ASN-TYR-V AL-V AL-THR-ASP-HIS covalently linked to a Cysteine and conjugated to keyhole limpet hemocyanin (KLH).  CDX-110 is a therapeutic cancer vaccine candidate.

Compound means a peptide that comprises at least a portion of an EGFRvIII comprising the amino acid sequence LYS-LYS-GLY-ASN-TYR. as an antigen. alone or as a component of a larger peptide. protein or molecule.

EGFRvIII means EGFR variant III peptide, a variant of EGFR. previously referred to as a type II variation of EGFR, consisting of the amino acid sequence of EGFR as set forth in GenBank Accession No, CAA2524Q. except amino acids number 1 through 24 have been deleted and where amino acids number 30 through 297 have been replaced by a Glycine. and naturally occurring variants thereof.

Additional Component means a therapeutically active (alone or in combination) adjuvant. immunomodulator. immunoregulator or hapten.

APC Product means an antibody or fragment thereof. that is targeted to an antigen-presenting cell (APC) and that comprises or is connected to a Compound or Licensed Product.

Patents are for the EGFRvlll Patent Family 1, 2, and 3.

Field of Use
The field of use for CDX-110 includes the treatment of glioblastoma multiforme or GBM.

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain.

Rindopepimut is an experimental therapeutic cancer vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII) in patients with Glioblastoma Multiforme (GBM)

IPSCIO Record ID: 256278

License Grant
On the Effective Date the Parties have terminated a certain Collaboration Agreement, and with this agreement, the Parties desire to reallocate the rights and responsibilities of the Parties with respect to further research and development of the GM-CSF Target.

Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.

Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.

License Property
BiTE Product means any composition or formulation consisting of or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells.

GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.

Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.

Field of Use
The field for Patent 5,223,409 is solely in the field of manufacture, use or sale of Single Chain Antibodies.

The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.

Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 256279

License Grant
The German Licensor grants an exclusive. even as to Licensor, right and license under the Licensed Technology, to make, have made, use, offer for sale, sell, and import Collaboration Products in the Territory for any use in humans.

Licensor grants a worldwide, co-exclusive, with Licensor, right and license, with the right to grant sublicenses, under the Licensor Collaboration Technology to make, have made, use, offer for sale, sell, and import any product that is not a BiTE Product for any use in humans.

License Property
Collaboration Product means any composition or formulation containing a BiTE Molecule binding to a Collaboration Target.

BiTE Molecule means a polypeptide comprising a bi-specific Single Chain Antibody binding to T-cells.

Target means a cell-surface antigen.  The list of proprietary targets is epha2, alpha – V, and, beta-3.

BiTE(R) molecules are part of a novel class of antibody derivatives that may have the potential to selectively direct and activate the human immune system to act against cancer cells. This action is believed to occur as a result of the molecule's stimulation of T cells to target and destroy cancer cells that express a specific antigen.

Field of Use
This product collaboration is useful for the development of antibody-based pharmaceutical products.

BiTE molecule targeting CD19 is for the potential treatment of certain lymphomas.

IPSCIO Record ID: 256218

License Grant
The Licensor of Israel grants an exclusive, worldwide royalty bearing license, with the right to grant sublicenses through multiple tiers,  under the Licensed IP Rights to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, import, export, commercialize and otherwise exploit Licensed Products for use in the Field.
License Property
The licensed patents refer to Chimeric Receptor Genes and Cells Transformed Therewith.

Eshhar patents US 5,906,936
US 7,741,465, Eshhar et al

Eshhar-NIH patent US 8,211,422, Eshhar et al

Eshhar-NIH pending application [US 13/281,560, Eshhar et al

KTE-C19 is an anti-CD19 CAR T cell therapy. CD19 is a protein expressed on the cell surface of B cell lymphomas and leukemias.

Field of Use
The Field shall mean, collectively, all oncology applications and all other applications, as mutually agreed in writing by the parties and attached as an amendment to this Agreement.

IPSCIO Record ID: 346459

License Grant
For the Sublicense to Licensed Patents, Licensor grants a non-exclusive sublicense under the Licensed Patents for the Term of this Agreement to develop, have developed, make, have made, use, have used, import, offer for sale, have offered for sale, sell and have sold Licensed Products and Licensed Services, in each case, in the Field in the Territory.
License Property
CART-19 shall mean a chimeric antigen receptor T cell directed against CD 19.

Licensed Patents shall mean Chimeric receptors with 4-1BB stimulatory signaling domain, and, shall specifically exclude 7,435,596 and 8,026,097 , and any other patent or patent application that claims priority to, or common priority with, or is a divisional, continuation, re-issue, renewal, reexamination, substitution or extension of any patent or patent application identified in clause (a) above that contains only claims directed to the expansion of natural killer NK cells.

Licensed Product shall mean any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under this Agreement. For the avoidance of doubt, as of the Effective Date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, as defined under this Agreement.

Penn Construct shall mean a CART- 19 that includes a 4-1BB signaling domain and a CD3~ signaling domain.

Licensor is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer.

Field of Use
Patents cover the technology for chimeric antigen receptors (CARs) used in cancer immunotherapies.

IPSCIO Record ID: 344529

License Grant
By the original agreement, Licensor, a not-for-profit pediatric treatment and research facility, grants an exclusive license to develop, make, have made, use, import, offer for sale, sell, and have sold the Licensed Products and Licensed Services worldwide under the Patent Rights in the Licensed Field.
License Property
The licensed property is the invention(s) titled Chimeric Receptors with 4-1BB Stimulatory Signaling Domain.

This amendment #2 adds that Licensed Products shall mean, when used in relation to A Third Party Agreement, any material, cell, composition or drug, the manufacture, use, importation, offer for sale or sale of which would infringe any Valid Claim but for the license granted under the Third Party Sublicense Agreement. For the avoidance of doubt, as of the Third Party Sublicense Agreement. effective date, the Penn Construct and any product incorporating the Penn Construct are Licensed Products, and,

Adds that Licensed Services shall mean, when used in relation to the Third Party Sublicense Agreement, any service using a Licensed Product.

Penn Construct shall mean a CART-19 that includes a 4-1BB signaling domain and a CD3~ signaling domain.  CART-19 shall mean a chimeric antigen receptor T cell directed against CD 19.

Patent Rights are amended to read Patent Rights, when used in relation to the Third Party Sublicense Agreement, shall mean the patent and patent applications listed in the Third Party Sublicense Agreement;  and specifically exclude 7,435,596 and 8,026,097.

Field of Use
The shall mean all therapeutic, diagnostic, preventative and palliative uses.

Licensee is a biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Chimeric antigen receptor (CAR) recognize and kill cancer cells.

IPSCIO Record ID: 372551

License Grant
For the Grant of Licensee Product License by Licensor of the United Kingdom To Licensee, In the event Licensor notifies Licensee above that a Nominated Target has passed the Licensor Gatekeeping Procedure, then upon receipt by Licensor of the applicable Acceptance Fee, Licensor agrees to grant and hereby grants to a non-exclusive license, with the right to sublicense, under the Licensor Antibody Phage Display Patents and Licensor Know-How to Exploit Products against such Nominated Target in the Territory, the Licensee Product License.

For the Grant of Other Licenses for Other Products, Licensor grants with effect from 3 January 2003 to Licensee a non-exclusive license in the Territory, with the right to sublicense, under the Licensor Antibody Phage Display Patents and the Licensor Know How for any purpose not already covered by the provisions of this Agreement, Other Purposes, including to Exploit any product, other than a Therapeutic Antibody Product, Diagnostic Antibody Product or Research Product, whose development, manufacture, use or sale would, absent the license hereunder, infringe Valid Claims of the Licensor Antibody Phage Display Patents or utilize the Licensor Know-How, Other Product License.

License Property
Licensor is the owner or exclusive licensee of the Licensor Antibody Phage Display Patents.

Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

Licensor Product means any preparation for the treatment or prevention of disease, infection, or other condition in humans for any indication which contains, comprises, or the process of development or manufacture of which utilizes a Licensee Licensable Antibody, or, any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction, or disease management of a disorder for any indication which contains, comprises or the process of development or manufacture of which utilizes a Licensee Licensable Antibody.

Diagnostic Antibody Product means any preparation in the form of a device, compound, kit or service with utility in the diagnosis, prognosis, prediction or disease management of a disorder for any indication which contains, comprises or the process of development or manufacture of which utilizes a Licensor Licensable Antibody.

Target shall mean
— a polynucleotide sequence corresponding to a sequence identified in a publicly available curated
database such as GenBank® by means of an accession number or similar sequence information
that uniquely identifies that sequence;
— a non-proteinaceous antigen that is uniquely identifiable in a routine manner using publicly
available curated databases and/or such other suitable written material as is available.

The Licensor Know-How includes
— Training Manual 'Antibody Phage Display' 2002.
— mammalian expression IgG vectors
—-pEU1 .2 (human gamma-1 heavy chain)
—-pEU3.2 (human kappa light chain)
—-pEU4.2 (human lambda light chain), and,
—-pEU8.2 (human gamma-4 heavy chain).

Field of Use
Antibody phage display is a versatile, in vitro selection technology that can be utilized to discover high affinity antibodies specific to a wide variety of antigens (94).

The Field of Use means research and development of human or non-human therapeutics and human or nonhuman in vitro diagnostic or research reagent uses only and not any in vivo diagnostics, purifications or separations, or other industrial purposes.

IPSCIO Record ID: 319188

License Grant
Licensor hereby grants to Licensee a revenue-bearing license under the Licensor Licensed Patents and the Licensor Licensed Know-How to (1) Develop Licensed Antibodies and Products in the U.S., (2) Manufacture and use Licensed Antibodies and Products in the U.S. solely for Development purposes, (3) Commercialize, sell, offer for sale and import Products in the U.S. and (4) Manufacture and use Products in the U.S. solely for Commercialization purposes. The licenses set forth in subparts (1) and (2) above shall be co-exclusive and the licenses set forth in subparts (3) and (4) above shall be exclusive.

Licensor hereby grants to Licensee a royalty-bearing license under the Licensor Licensed Patents and the Licensor Licensed Know-How to (1) Develop Licensed Antibodies and Products in the Royalty Territory, (2) Manufacture and use Licensed Antibodies and Products in the Royalty Territory solely for Development purposes, (3) Commercialize, sell, offer for sale and import Products in the Royalty Territory and (4) Manufacture and use Products in the Royalty Territory solely for Commercialization purposes. The licenses set forth in subparts (1) and (2) above shall be co-exclusive and the licenses set forth in subparts (3) and (4) above shall be exclusive.

Licensor hereby grants to Licensee a non-exclusive license under the Queen Patents to (1) Develop Licensed Antibodies and Products in the Territory, (2) Manufacture and use Licensed Antibodies and Products in the Territory solely for Development purposes, (3) Commercialize, sell, offer for sale and import Products in the Territory and (4) Manufacture and use Products in the Territory solely for Commercialization purposes. Such license shall be revenue-bearing with respect to Products Commercialized in the U.S. and royalty-bearing with respect to Products Commercialized in the Royalty Territory.

License Property
CS1 antibodies (Target) includes antibodies known as HuLuc63 and PDL-241.

HuLuc63 means the Antibody that (i) contains the amino acid sequence set forth in this agreement and (ii) is the subject of an existing IND of Licensor prior to the Effective Date.

PDL-241 means the Antibody containing the amino acid sequence set forth in this agreement.

PDL-241 Product means any Product that contains or incorporates PDL-241.

Product means any pharmaceutical product that contains or incorporates a Licensed Antibody.

Licensed Antibody means an Existing Antibody or Future Antibody or, solely if Licensee exercises the Licensee Option, an Option Antibody.

Antibody means any (i) antibody, (ii) protein comprising at least one CDR portion thereof (including bispecific antibodies, single chain antibodies, domain antibodies and immunoconjugated antibodies) or (iii) adnectin; in each of (i), (ii) and (iii), whether human, humanized, chimeric, murine, synthetic or from any other source, that (a) has been raised, engineered or otherwise optimized to bind specifically and directly to the Target (whether exclusively or in addition to any other target such Antibody may modulate) and (b) competes for binding to the Target with a naturally occurring ligand of the Target, interferes with Target-Target interaction, or, once bound to the Target, exhibits antagonistic activity against the Target, agonist activity against the Target, ADCC (antibody dependent cellular cytotoxity) and/or other Fc-mediated effector function.

Queen Patent means any Patent that (a) is set forth in this agreement; or (b) is a continuation, divisional, continuation-in-part, substitution, extension, registration, confirmation, reissue, re-examination, supplementary protection certificates, confirmation patents, patent of additions or renewal of, or issues from, any Patent described in clause (a) above; or (c)  is a foreign counterpart of any of (a) or (b) above.
5,585,089 – Humanized immunoglobulins
5,693,761 – Polynucleotides encoding improved humanized immunoglobulins
5,693,762 – Humanized immunoglobulins

Licensor Licensed Patents means all Patents that are
(a) Controlled by Licensor and its Affiliates, including patents Controlled jointly with Licensee, as of the Effective Date and (i) claim a Licensed Antibody, a composition containing a Licensed Antibody (e.g., a formulation containing a Licensed Antibody), or the manufacture or use of a Licensed Antibody (or a composition containing a Licensed Antibody); or (ii) are necessary or reasonably useful for Licensee to perform its obligations to the Collaboration under the Agreement; or (b) Controlled by Licensor and its Affiliates, including Patents Controlled jointly with Licensee, during the term of this Agreement and (i) claim an Invention; or (ii) are a continuation, divisional, continuation-in-part (solely to the extent claiming subject matter disclosed in a Patent described in clause (a) above), foreign counterpart, substitution, extension, registration, confirmation, reissue, re-examination, supplementary protection certificates, confirmation patents, patent of additions or renewal of, or issue from, any Patent described in clause (a) above.

Notwithstanding the foregoing, Licensor Licensed Patents shall exclude (1) the Queen Patents and (2) all Patents claiming BioBetter Technology. The Licensor Licensed Patents, include, without limitation, the Patents set forth on this agreement.
5,225,539 – Recombinant altered antibodies and methods of making altered antibodies
6,548,640 Bl – Altered antibodies
5,849,522 – Enhancer for eukaryotic expression systems

Target IP means (a) U.S. Patent Nos. 7,253,256 and 7,214,777, and (b) U.S.
and ex-U.S. patents and pending patent applications that claim priority thereto, have a common
priority claim therewith or are a foreign equivalent thereof, to the extent such patents and
pending patent applications (i) claim the Target, nucleotide sequences (including vectors)
encoding the Target, host cells containing any of the foregoing, Antibodies and/or methods of
manufacturing or using any of the foregoing, or (ii) are otherwise necessary for
Commercialization of a Product.
7,253,256 – Polypeptides encoded by a nucleic acid are expressed in esophageal and kidney tumor
7,214,777 – Secreted and transmembrane polypeptides and nucleic acids encoding the same

Field of Use
The field of use is for the development of certain CS1 antibodies to be marketed for use in new therapies and treatment programs.

Licensee is a worldwide, research-based pharmaceutical company, engaged in the discovery, development, manufacturing and marketing of new therapies and treatment programs.

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

IPSCIO Record ID: 3200

License Grant
The Licensee exclusively licensed certain patents related to EphA3 from the Licensor, that formed the basis for the KB004 program.
License Property
This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Two alternatively spliced transcript variants have been described for this gene.  

Anti-EphA3 has shown encouraging preclinical proof-of-concept results in multiple tumor models. The xenograft studies we conducted show that the anti-EphA3 antibody causes growth inhibition in EphA3-positive tumors, as well as in tumors that do not express EphA3 (the latter presumably through the effect on tumor vasculature).

Cancer cells are killed by KB004 binding to EphA3 through apoptosis, or ADCC, at relatively low concentrations. KB004 ex vivo selectively targets and kills leukemic stem cells, but not normal hematopoietic stem cells. In ex vivo assays of these cells, KB004 appears to kill
all cells expressing EphA3.

Field of Use
Under the agreement, the Licensee has rights to develop human antibodies that bind to or modulate EphA3.

IPSCIO Record ID: 290397

License Grant
Licensor is granting a non-exclusive license under the Queen Patents for the purpose of conducting research, development and commercial activities on humanized antibodies directed against up to three Licensee Antigens.

For the License Grant, Licensor grants a nonexclusive, non-sublicensable, sublicense under the exclusive rights granted to Licensor herein to research, develop, make and use (but not to, have made, sell, or offer for sale) Licensed Biologic Products for Licensee internal research only.

Licenses to Licensee Under the Queen Patents
Licensor grants through the fifth anniversary of the Effective Date the right, upon written notice to Licensor, to receive licenses under the Licensor Antibody Humanization Patent Rights for the Licensee Antigens. Licensee shall identify each Licensee Antigen prior to IND Filing for the associated Licensed Queen Product. Each license shall be a nonexclusive, worldwide, transferable, license under the Licensor Antibody Humanization Patent Rights to make, have made, use, import, offer for sale and sell or otherwise dispose of Licensed Queen Product pursuant to a Licensor License Agreement to be executed by the Parties after such written notice.

License Property
Licensor has certain patents and patent applications concerning humanized antibodies and antibody humanization technology including certain patents and patent applications that are sometimes referred to as the Queen Patents.

Licensor Antigens shall mean an antigen selected by Licensee and approved by Licensor for the grant by Licensor to Licensee of a license to its Licensor Antibody Humanization Patent Rights, up to a limit of three antigens. Licensee shall identify each such Licensee Antigen after the Effective Date, but no later than the IND filing date for each associated Licensed Queen Product.

Licensed Queen Products shall mean any Antibody that binds to an Licensee Antigen whose development, manufacture, import, export, use, offer for sale or sale would infringe a Valid Queen Claim absent a license to one or more of the Queen Patents.

Field of Use
Therapeutic Field shall mean any human and/or animal use.

Diagnostic Field shall mean any use for the diagnosis, prognosis, or monitoring of a human disease or disorder.

IPSCIO Record ID: 280819

License Grant
For the Research the German Licensor grants a non-exclusive research license under Licensor Background Inventions and Licensors rights in Collaboration Data, Collaboration Materials and Collaboration Inventions, to perform its obligations under the Collaboration Plan.

For the Commercial License,  Licensor grants an exclusive, worldwide license to make, have made, use, have used, sell, have sold, offer for sale, import and have imported Licensed Products for use in the Field directed to such Licensee Target under Licensor Background Inventions, and under Licensors rights in all Patent Rights and Collaboration Inventions and Collaboration Material pertaining to such Licensee Target and Licensed Products, or the uses thereof in the Field.

License Property
Licensors HuCAL Technologies shall mean the HuCAL library and associated technologies.   The library data is for a Design of Human Combinatorial Antibody Library-Fab (HuCAL-Fab).
Field of Use
The field shall mean all therapeutic indications.  With this agreement, the Parties will collaborate in the discovery and development of human monoclonal antibodies against certain specified Licensee Targets,  to generate and characterize antibodies and optimize those antibodies and  use their expertise in developing antibodies in pre-clinical and clinical settings.

The two companies will collaborate on the development of human antibodies for the treatment of cancer.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.